Seres Therapeutics is a company.
Seres Therapeutics has raised $69.0M across 3 funding rounds.
Key people at Seres Therapeutics.
Seres Therapeutics was founded by David Berry (Founder).
Seres Therapeutics has raised $69.0M in total across 3 funding rounds.
Seres Therapeutics was founded by David Berry (Founder).
Seres Therapeutics has raised $69.0M in total across 3 funding rounds.
Seres Therapeutics's investors include ARCH Venture Partners, Flagship Ventures, Daniel Lynch, Third Rock Ventures.
Seres Therapeutics is a commercial-stage biotechnology company pioneering live biotherapeutics—orally administered drugs comprised of rationally selected bacterial consortia—to treat serious diseases by modulating the human microbiome.[1][2][4][5] Its flagship product, VOWST, is the first FDA-approved oral live biotherapeutic for preventing Clostridioides difficile (C. diff) recurrence in medically vulnerable patients, with a pipeline targeting bacterial bloodstream infections, antimicrobial-resistant (AMR) infections, and GI-related immune diseases.[1][2][4][6] The company serves patients with unmet needs in dysbiosis-related conditions, solving problems like recurrent infections and inflammation where traditional treatments fail by restoring microbiome function for durable efficacy.[1][5][6] Founded in 2012, Seres has achieved key milestones like VOWST's approval and its sale to Nestlé Health Science in September 2024, demonstrating strong growth momentum in the microbiome therapeutics field.[4][5]
Seres Therapeutics was founded in 2012 by a team of microbiome experts, including key scientific leader Dr. Matthew Henn, whose background includes research on microbial physiology at the Broad Institute of MIT and Harvard, where he served as Director of Viral Genomics.[4][5] The idea emerged from pioneering insights into the microbiome's role in human disease, translating environmental and genomic microbial studies into therapeutics to address dysbiosis—the imbalance in gut bacteria linked to serious illnesses.[1][4][6] Early traction came from building a robust pipeline and achieving the FDA approval of VOWST as the first oral live biotherapeutic, marking a pivotal moment that validated their approach and led to its commercialization and subsequent sale.[1][4]
Seres rides the microbiome therapeutics trend, harnessing gut bacteria to treat immune, inflammatory, and infectious diseases amid rising antimicrobial resistance (AMR) and C. diff epidemics.[2][6] Timing is ideal as microbiome science matures—post-VOWST approval in 2023 and its 2024 sale—validating the field and accelerating adoption where antibiotics fall short.[1][4] Market forces like growing recognition of dysbiosis in cancers, infections, and GI disorders favor Seres, with its platform influencing biotech by proving live biotherapeutics' viability and inspiring ecosystem-wide investment in microbial modulation.[5][6] This positions microbiome therapies as a mainstream pillar in precision medicine.
Seres is poised to expand its pipeline into AMR prevention and immune diseases, leveraging platform insights from VOWST's success and post-sale resources from Nestlé.[2][4] Trends like AMR crises and microbiome-host interaction research will shape its path, potentially yielding more approvals and partnerships. Its influence may evolve from pioneer to category leader, redefining treatments for vulnerable patients and solidifying microbiome therapeutics' role in medicine—echoing its founding mission to transform lives through biological innovation.[1][3]
Key people at Seres Therapeutics.
Seres Therapeutics has raised $69.0M across 3 funding rounds. Most recently, it raised $48.0M Series C in December 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2014 | $48.0M Series C | ARCH Venture Partners, Flagship Ventures | |
| May 1, 2014 | $10.0M Series B | ARCH Venture Partners, Flagship Ventures | |
| Nov 1, 2013 | $11.0M Series A | ARCH Venture Partners, Flagship Ventures, Daniel Lynch, Third Rock Ventures |
